Updates are available Correction dated 2021-02-05
Click to view Correction: https://doi.org/10.1038/s41591-021-01246-4
-
Authors
Yuen, Kobe C.
Liu, Li-Fen
Gupta, Vinita
Madireddi, Shravan
Keerthivasan, Shilpa
Li, Congfen
Rishipathak, Deepali
Williams, Patrick
Kadel, Edward E. III http://orcid.org/0000-0003-3030-6628
Koeppen, Hartmut
Chen, Ying-Jiun
Modrusan, Zora
Grogan, Jane L. http://orcid.org/0000-0003-4062-7134
Banchereau, Romain http://orcid.org/0000-0001-6916-6445
Leng, Ning
Thastrom, AnnChristine
Shen, Xiadong
Hashimoto, Kenji
Tayama, Darren
van der Heijden, Michiel S.
Rosenberg, Jonathan E.
McDermott, David F. http://orcid.org/0000-0002-2675-5095
Powles, Thomas
Hegde, Priti S.
Huseni, Mahrukh A. http://orcid.org/0000-0001-8166-3401
Mariathasan, Sanjeev http://orcid.org/0000-0001-5034-773X
-
Funding
Funding for this research was provided by:
Genentech, Inc
Roche/Genentech, Inc
Roche
Dana-Farber/Harvard Cancer Center (5P50CA101942)
- License Information
-
More Information
Article History
Received: 16 July 2019
Accepted: 30 March 2020
First Online: 11 May 2020
Change Date: 5 February 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-021-01246-4
Competing interests
: K.C.Y., L.-F.L., V.G., C.L., D.P., P.W., E.E.K., H.K., S.M., S.K., Y.-J.C, Z.M., J.L.G., R.B., N.L., A.C.T., X.S., D.T., P.S.H., M.A.H. and S.M. are employees of Genentech. K.H. is an employee of Roche Products. D.F.M. reports a consulting/advisory role for Bristol-Myers Squibb, Merck, Roche/Genentech, Pfizer, Exelixis, Novartis, Eisai, X4 Pharmaceuticals and Array BioPharma; and reports that his home institution receives research funding from Prometheus Laboratories. T.P. reports honoraria and consulting/advisory roles with Roche/Genentech, Bristol-Myers Squibb and Merck; a consulting/advisory role with AstraZeneca and Novartis; research funding from AstraZeneca/MedImmune and Roche/Genentech; and other relationships with Ipsen and Bristol-Myers Squibb. J.E.R. has received trial funding and consulting fees from Roche Genentech, Bayer, Seattle Genetics, AstraZeneca, Astellas and QED Therapeutics. M.S.v.d.H. has advisory board agreements with Roche Genentech, Astellas and AstraZeneca and has received grants from Astellas.
